Hypercalcemia Diagnosis and Management

Initial Evaluation

The American College of Chest Physicians recommends measuring serum calcium, intact parathyroid hormone (iPTH), parathyroid hormone-related protein (PTHrP), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, phosphorus, magnesium, albumin, creatinine, and blood urea nitrogen to determine the underlying etiology of hypercalcemia 1, 2, 3
Calculate corrected calcium using the formula: Corrected calcium (mg/dL) = Total calcium (mg/dL) - 0.8 × [Albumin (g/dL) - 4], or preferably measure ionized calcium directly 3

The American College of Chest Physicians classifies hypercalcemia severity as mild (10-11 mg/dL), moderate (11-12 mg/dL), or severe (>14 mg/dL) to guide urgency of intervention 1, 2, 4
Moderate hypercalcemia is characterized by symptoms such as polyuria, polydipsia, nausea, confusion, vomiting, and abdominal pain 1, 2, 4

Primary hyperparathyroidism is indicated by hypercalcemia with elevated or inappropriately normal iPTH, hypophosphatemia, and hyperchloremic metabolic acidosis 1, 2, 4
Malignancy-associated hypercalcemia is characterized by rapid onset, higher calcium levels, elevated PTHrP, and low or normal 1,25-dihydroxyvitamin D 1, 2, 4
Vitamin D-mediated hypercalcemia is indicated by elevated 1,25-dihydroxyvitamin D in granulomatous diseases or lymphomas, and elevated 25-hydroxyvitamin D in vitamin D intoxication 1, 2, 4

The American College of Chest Physicians recommends initiating IV normal saline hydration immediately to correct hypovolemia and promote calciuresis, targeting urine output ≥100 mL/hour 3, 5
Administer IV bisphosphonates, with zoledronic acid preferred over pamidronate, after starting hydration 1, 2, 3, 5
Add calcitonin for immediate short-term management of severe symptomatic hypercalcemia while waiting for bisphosphonates to take effect 3
Use loop diuretics (furosemide) only after volume repletion in patients with renal or cardiac insufficiency to prevent fluid overload 1, 2, 6

Glucocorticoids are the primary treatment for vitamin D-mediated hypercalcemia (sarcoidosis, lymphomas, vitamin D intoxication, granulomatous disorders) 1, 2, 4
Denosumab (120 mg subcutaneously) is indicated for refractory hypercalcemia, especially in patients with renal impairment where bisphosphonates are contraindicated 3
Dialysis is reserved for severe hypercalcemia complicated by kidney failure 5

Parathyroidectomy is indicated for primary hyperparathyroidism in patients with symptomatic disease, osteoporosis, impaired kidney function, kidney stones, hypercalciuria, age <50 years, or calcium >0.25 mmol/L above upper normal limit 4
Treat the underlying malignancy when possible, as this is essential for long-term control of malignancy-associated hypercalcemia 4, 5

Monitor serum calcium, renal function, and electrolytes regularly to assess treatment effectiveness 3, 4, 5
Watch for bisphosphonate complications: renal toxicity and osteonecrosis of the jaw with chronic use 3, 6
Avoid vitamin D supplements in patients with hypercalcemia, particularly in early childhood 3, 4, 5

The Endocrine Society recommends measuring intact PTH level as the single most important test to distinguish PTH-dependent causes from PTH-independent causes of hypercalcemia 7
Lithium can cause hypercalcemia, and a detailed medication history is essential for diagnosis 7

If PTH is elevated or inappropriately normal, it indicates primary hyperparathyroidism, and no further workup is needed if classic PHPT is confirmed 7
The Endocrine Society suggests that PTH assays vary between laboratories due to lack of standardization, and trend monitoring is more reliable than absolute values in some contexts 7